Mangafodipir ( DrugBank: Mangafodipir )


2 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1
58Hypertrophic cardiomyopathy1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01326715
(ClinicalTrials.gov)
October 17, 201330/3/2011Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple SclerosisManganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple SclerosisMultiple SclerosisDrug: Mangafodipir (Teslascan)National Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted18 Years70 YearsAll17Phase 1United States

58. Hypertrophic cardiomyopathy


Clinical trials : 119 Drugs : 163 - (DrugBank : 45) / Drug target genes : 48 - Drug target pathways : 161
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03607669
(ClinicalTrials.gov)
June 1, 201820/7/2018Manganese-Enhanced Magnetic Resonance Imaging of the MyocardiumManganese-Enhanced Magnetic Resonance Imaging: Applications in CardiomyopathyIschemic Cardiomyopathy;Dilated Cardiomyopathy;Hypertrophic CardiomyopathyOther: Mangafodipir trisodiumUniversity of EdinburghNULLUnknown status18 Years65 YearsAll90United Kingdom